Cargando…

Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies

Establishing a prognosis at hospital admission after stroke is a major challenge. Inflammatory processes, hemostasis, vascular injury, and tissue remodeling are all involved in the early response to stroke. This study analyzes whether 22 selected biomarkers, sampled at admission, predict clinical ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Meseguer, Elena, Diallo, Devy, Labreuche, Julien, Charles, Hugo, Delbosc, Sandrine, Mangin, Gabrielle, Monteiro Tavares, Linsay, Caligiuri, Giuseppina, Nicoletti, Antonino, Amarenco, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763291/
https://www.ncbi.nlm.nih.gov/pubmed/33322093
http://dx.doi.org/10.3390/jcm9124028
_version_ 1783627983674671104
author Meseguer, Elena
Diallo, Devy
Labreuche, Julien
Charles, Hugo
Delbosc, Sandrine
Mangin, Gabrielle
Monteiro Tavares, Linsay
Caligiuri, Giuseppina
Nicoletti, Antonino
Amarenco, Pierre
author_facet Meseguer, Elena
Diallo, Devy
Labreuche, Julien
Charles, Hugo
Delbosc, Sandrine
Mangin, Gabrielle
Monteiro Tavares, Linsay
Caligiuri, Giuseppina
Nicoletti, Antonino
Amarenco, Pierre
author_sort Meseguer, Elena
collection PubMed
description Establishing a prognosis at hospital admission after stroke is a major challenge. Inflammatory processes, hemostasis, vascular injury, and tissue remodeling are all involved in the early response to stroke. This study analyzes whether 22 selected biomarkers, sampled at admission, predict clinical outcomes in 153 stroke patients treated by thrombolysis and mechanical endovascular treatment (MET). Biomarkers were related to hemostasis (u-plasminogen activator/urokinase (uPA/urokinase), serpin E1/PAI-1, serpin C1/antithrombin-III, kallikrein 6/neurosin, alpha 2-macroglobulin), inflammation[myloperoxidase (MPO), chemokine ligand 2/monocyte chemoattractant protein-1 chemokine (CCL2/MCP-1), adiponectin, resistin, cell-free DNA (cDNA), CD40 Ligand (CD40L)], endothelium activation (Vascular cell adhesion protein 1 (VCAM-1) intercellular adhesion molecule 1 (ICAM-1), platelet endothelial cell adhesion molecule 1 (CD31/PECAM-1)], and tissue remodeling (total cathepsin S, osteopontin, cystatin C, neuropilin-1, matrix metallopeptidase 2 (MMP-2), matrix metallopeptidase 3 (MMP-3), matrix metallopeptidase 9 (MMP-9), matrix metallopeptidase 13 (MMP-13)]. Correlations between their levels and excellent neurological improvement (ENI) at 24 h and good outcomes (mRS 0–2) at three months were tested. Osteopontin and favorable outcomes reached the significance level (p = 0.008); the adjusted OR per SD increase in log-transformed osteopontin was 0.34 (95%CI, 0.18–0.62). The relationship between total cathepsin S and MPO with ENI, was borderline of significance (p = 0.064); the adjusted OR per SD increase in log-transformed of total cathepsin S and MPO was 0.54 (95%CI, 0.35–0.81) and 0.51 (95%CI, 0.32–0.80), respectively. In conclusion, osteopontin levels predicted three-month favorable outcomes, supporting the use of this biomarker as a complement of clinical and radiological parameters for predicting stroke prognosis.
format Online
Article
Text
id pubmed-7763291
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77632912020-12-27 Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies Meseguer, Elena Diallo, Devy Labreuche, Julien Charles, Hugo Delbosc, Sandrine Mangin, Gabrielle Monteiro Tavares, Linsay Caligiuri, Giuseppina Nicoletti, Antonino Amarenco, Pierre J Clin Med Article Establishing a prognosis at hospital admission after stroke is a major challenge. Inflammatory processes, hemostasis, vascular injury, and tissue remodeling are all involved in the early response to stroke. This study analyzes whether 22 selected biomarkers, sampled at admission, predict clinical outcomes in 153 stroke patients treated by thrombolysis and mechanical endovascular treatment (MET). Biomarkers were related to hemostasis (u-plasminogen activator/urokinase (uPA/urokinase), serpin E1/PAI-1, serpin C1/antithrombin-III, kallikrein 6/neurosin, alpha 2-macroglobulin), inflammation[myloperoxidase (MPO), chemokine ligand 2/monocyte chemoattractant protein-1 chemokine (CCL2/MCP-1), adiponectin, resistin, cell-free DNA (cDNA), CD40 Ligand (CD40L)], endothelium activation (Vascular cell adhesion protein 1 (VCAM-1) intercellular adhesion molecule 1 (ICAM-1), platelet endothelial cell adhesion molecule 1 (CD31/PECAM-1)], and tissue remodeling (total cathepsin S, osteopontin, cystatin C, neuropilin-1, matrix metallopeptidase 2 (MMP-2), matrix metallopeptidase 3 (MMP-3), matrix metallopeptidase 9 (MMP-9), matrix metallopeptidase 13 (MMP-13)]. Correlations between their levels and excellent neurological improvement (ENI) at 24 h and good outcomes (mRS 0–2) at three months were tested. Osteopontin and favorable outcomes reached the significance level (p = 0.008); the adjusted OR per SD increase in log-transformed osteopontin was 0.34 (95%CI, 0.18–0.62). The relationship between total cathepsin S and MPO with ENI, was borderline of significance (p = 0.064); the adjusted OR per SD increase in log-transformed of total cathepsin S and MPO was 0.54 (95%CI, 0.35–0.81) and 0.51 (95%CI, 0.32–0.80), respectively. In conclusion, osteopontin levels predicted three-month favorable outcomes, supporting the use of this biomarker as a complement of clinical and radiological parameters for predicting stroke prognosis. MDPI 2020-12-13 /pmc/articles/PMC7763291/ /pubmed/33322093 http://dx.doi.org/10.3390/jcm9124028 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Meseguer, Elena
Diallo, Devy
Labreuche, Julien
Charles, Hugo
Delbosc, Sandrine
Mangin, Gabrielle
Monteiro Tavares, Linsay
Caligiuri, Giuseppina
Nicoletti, Antonino
Amarenco, Pierre
Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies
title Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies
title_full Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies
title_fullStr Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies
title_full_unstemmed Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies
title_short Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies
title_sort osteopontin predicts three-month outcome in stroke patients treated by reperfusion therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763291/
https://www.ncbi.nlm.nih.gov/pubmed/33322093
http://dx.doi.org/10.3390/jcm9124028
work_keys_str_mv AT meseguerelena osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies
AT diallodevy osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies
AT labreuchejulien osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies
AT charleshugo osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies
AT delboscsandrine osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies
AT mangingabrielle osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies
AT monteirotavareslinsay osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies
AT caligiurigiuseppina osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies
AT nicolettiantonino osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies
AT amarencopierre osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies